Luis Rico | Oncology | Editorial Board Member

Dr. Luis Rico | Oncology | Editorial Board Member

Managing Director | Hospital Aleman | Argentina

Dr. Luis Rico is a distinguished clinician–researcher at Hospital Alemán, Buenos Aires, renowned for his impactful contributions to urology, with a strong focus on endourology, advanced laser technologies, and minimally invasive surgical innovation. His work centers on improving procedural precision, optimizing perioperative outcomes, and enhancing patient safety in the management of complex urolithiasis. By integrating next-generation laser systems, cutting-edge endoscopic platforms, and refined surgical protocols, Dr. Rico continually advances evidence-based approaches that elevate standards of clinical care. With an active and growing academic footprint, he has authored numerous peer-reviewed publications addressing pivotal challenges in intrarenal surgery, flexible ureteroscopy, and comparative laser performance particularly evaluating modalities such as the Thulium Fiber Laser and HO:YAG systems. His research has expanded global understanding of operative efficiency, stone-free rates, laser–tissue dynamics, and postoperative recovery pathways. Dr. Rico collaborates extensively with international urology organizations, multidisciplinary surgical teams, and multicenter research networks, underscoring his commitment to shared scientific progress, surgical innovation, and clinical excellence. In addition to his research, he plays a key role in clinical training, contributes to multicenter trials, and advances patient-centered care through methodical, outcomes-driven practice. His scholarly contributions reflect a balanced blend of innovation, scientific rigor, and translational relevance, ensuring continued impact on the evolving landscape of urologic surgery and minimally invasive therapeutic strategies. Dr. Rico’s academic influence is further highlighted by his research metrics, which include 252 citations, 35 scientific documents, and an h-index of 9, reflecting both the quality and reach of his contributions to modern urological science.

Featured Publications

Rico, L., Blas, L., Álvarez Jaramillo, J., Filgueira, G., Soldano, J., & Contreras, P. (2025). Magneto Ho:YAG laser versus Thulium Fiber Laser for laser lithotripsy during flexible ureteroscopy with a flexible and navigable ureteral access sheath. International Urology and Nephrology.

Rico, L., Blas, L., Banda Ramos, L., Maqueda, M., Pizzarello, J., & Contreras, P. (2025). Thulium Fiber Laser versus Vapor Tunnel HO:YAG laser in retrograde intrarenal surgery: Which one has better laser ablation performance? World Journal of Urology.

Rico, L., Diaz-Zorita, V., Blas, L., Banda Ramos, L., Sabeh, P., & Contreras, P. (2025). Is the ablation stone efficacy and efficiency better with a flexible and navigable suction ureteric access sheath? World Journal of Urology.

Rico, L., Blas, L., Pizzarello, J., Banda-Ramos, L., & Contreras, P. (2024). Mini-endoscopic combined intrarenal surgery (mini-ECIRS) for complex urolithiasis. World Journal of Urology.

Rico, L., Maqueda, M., Blas, L., & Contreras, P. (2024). Anterograde placement of drug-coated balloon for ureteroileal anastomosis stricture. BMJ Case Reports.

Shahanavaj Khan | Cancer Science | Editorial Board Member

Assoc. Prof. Dr. Shahanavaj Khan | Cancer Science | Editorial Board Member

Associate Professor | Shri Ram College | India

Dr. Shahanavaj Khan is a distinguished researcher at King Saud University, Riyadh, specializing in cancer biology, pharmacology, and bioactive natural compounds. His work focuses on the anti-cancer and anti-inflammatory potential of plant-derived molecules, with particular emphasis on mechanisms involving apoptosis, Toll-Like Receptors, and microbiome-mediated cancer pathways. Dr. Khan employs advanced in-silico, in-vitro, and translational approaches to identify novel therapeutic targets and understand disease mechanisms, aiming to improve cancer diagnostics and treatment strategies. He has authored 54 publications in high-impact journals, contributing significantly to the understanding of prostate, lung, and other cancers, while integrating computational modeling with experimental validation. His research involves extensive collaborations with over 200 co-authors globally, demonstrating leadership in multidisciplinary oncology and pharmacology networks. Through his innovative studies on natural bioactive compounds and cancer therapeutics, Dr. Khan has contributed to the advancement of safer, more targeted treatment options, positively impacting patient care and public health. His scholarly work also underscores the importance of microbiome and receptor-mediated mechanisms in disease progression, bridging fundamental research with clinical applications. Dr. Khan’s academic influence and research productivity are reflected in his metrics 1,355 citations, 54 documents, and an h-index of 21.

Profiles: Scopus

Featured Publications

Khan, S., et al. (2025). Implication of Toll-Like Receptors in growth and management of health and diseases: Special focus as a promising druggable target to Prostate Cancer. [Review]. 7 citations.

Khan, S., et al. (2025). The implication of microbiome in lungs cancer: mechanisms and strategies of cancer growth, diagnosis and therapy. [Review]. 6 citations.

Khan, S., et al. (2025). Analysis of anti-cancer and anti-inflammatory activity in Typhonium flagelliforme rhizome extract by induction of apoptosis: An in-vitro study. Fitoterapia.

Dong Zhu | Organ-Defined Cancers | Best Researcher Award

Dong Zhu | Organ-Defined Cancers | Best Researcher Award

临沂大学 | China

AUTHOR PROFILE

SCOPUS ID

🏥MR. DONG ZHU: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Born in May 1999 in Zaozhuang, Shandong Province, China, Mr. Zhu Dong displayed an early aptitude for analytical thinking and computing. He embarked on his academic journey at Linyi University, earning a Bachelor of Engineering in Computer Science and Technology (2020–2022). Recognized for his diligence and academic excellence, he was admitted into the university’s graduate program, where he is currently pursuing a Master of Engineering in Computer Technology (2022–2025).

🩺PROFESSIONAL ENDEAVORS

While still a graduate student, Mr. Zhu has already made substantial strides in the field of medical image processing. He has co-developed advanced deep learning frameworks tailored to complex clinical imaging tasks, such as 3D liver segmentation and breast tumor analysis. His participation in collaborative and interdisciplinary projects reflects a forward-looking and adaptable research mindset.

🔬CONTRIBUTIONS AND RESEARCH FOCUS

Mr. Zhu’s primary research focus is on deep learning applications in medical image segmentation, with specific interests in:

  • 3D U-Net architectures
  • Attention mechanisms
  • Multi-scale feature fusion
  • Electrocardiogram (ECG) signal classification

🏆AWARDS AND HONOURS

  • National Scholarship, 2023–2024
  • First-Class Academic Scholarship, 2022–2023 & 2023–2024
  • Outstanding Communist Youth League Cadre, 2023–2024
  • Excellent Student Award, 2023–2024
  • Advanced Individual Award, 2023–2024

🌍IMPACT AND INFLUENCE

Though early in his career, Mr. Zhu’s models are contributing to more accurate, automated diagnosis systems in clinical imaging. His open-access publications and conference proceedings are cited in discussions around deep learning for medical applications, particularly in liver and breast imaging workflows. His interdisciplinary work is fostering stronger links between AI and clinical diagnostics.

🏆LEGACY AND FUTURE CONTRIBUTIONS

With a growing portfolio of first-author publications, Mr. Zhu is establishing himself as a rising researcher in AI-driven medical imaging. His focus on practical, clinically relevant problems positions him to contribute significantly to next-generation diagnostic technologies. In the coming years, he aims to expand his research to include multimodal imaging analysis, federated learning, and real-time diagnostic systems for point-of-care settings.

🧬CONCLUSION

Mr. Zhu Dong represents a new wave of interdisciplinary researchers who blend deep learning techniques with clinical needs. His trajectory reflects not only strong technical skills but also a deep commitment to improving healthcare through innovation. With continued support, mentorship, and exposure to global research networks, he is well-poised to lead breakthroughs in intelligent medical diagnostics.

 

📊🔬NOTABLE PUBLICATION:

3DMAU-Net: Liver Segmentation Network Based on 3D U-Net

Authors: Zhu, Dong; Ma, Tianyi; Yang, Mengzhu; Hu, Shunbo; Wang, Yongfang
Journal: Optoelectronics Letters
Year: 2025

Dr. Linxi Zhu – Cancer Genetics – Best Researcher Award

Dr. Linxi Zhu - Cancer Genetics - Best Researcher Award

Nanjing Drum Tower Hospital - China

Author Profile

Scopus

EARLY ACADEMIC PURSUITS:

Linxi Zhu commenced her academic journey at Nanjing University, where she pursued a Bachelor's degree from July 2015 to June 2020. Following her undergraduate studies, she continued her academic pursuit at the same institution, earning a Master's degree from July 2020 to June 2021. Linxi Zhu then advanced further in her educational journey, undertaking a Ph.D. program at Nanjing University from July 2021 to June 2023.

PROFESSIONAL ENDEAVORS:

Since September 2023, Linxi Zhu has been serving as a Surgeon at Nanjing Drum Tower Hospital, marking a significant transition from academic pursuits to practical application in the field of surgery.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER GENETICS :

Linxi Zhu's research has made notable contributions to the field of cancer genetics. Notably, her work titled "Loss of Claudin-1 incurred by DNMT aberration promotes pancreatic cancer progression" (published in Cancer Lett., 2024) sheds light on the molecular mechanisms underlying pancreatic cancer progression. Additionally, she has contributed to the development and validation of a nomogram for predicting post-operative abdominal infection in patients undergoing pancreaticoduodenectomy, as well as exploring the role of preoperative biliary drainage in postoperative outcomes after pancreaticoduodenectomy.

IMPACT AND INFLUENCE:

Zhu's research impact extends beyond pancreatic cancer, with contributions to the field of intrahepatic cholangiocarcinoma. Her collaborative work on high endothelial venule as a prognostic immune-related biomarker in patients with resected intrahepatic cholangiocarcinoma (published in Cell Prolif., 2023) underscores her diverse research interests.

ACADEMIC CITES:

Linxi Zhu has published in reputable journals, evident from her publications in Cancer Lett., Clin Chim Acta, Gland Surg, Cell Prolif., and Front Oncol. The citations received for her work demonstrate its scholarly significance and recognition within the academic community.

LEGACY AND FUTURE CONTRIBUTIONS:

Zhu's legacy lies in her comprehensive understanding of pancreatic cancer and related surgical interventions. Her research on individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in unresectable pancreatic cancer showcases innovative approaches. Looking forward, Linxi Zhu is poised to contribute further to the field, leaving a lasting impact on surgical and oncological research.

NOTABLE PUBLICATIONS

Development and validation of a nomogram for predicting post-operative abdominal infection in patients undergoing pancreaticoduodenectomy. 2022

Loss of Claudin-1 incurred by DNMT aberration promotes pancreatic cancer progression. 2024

 

 

 

 

 

Aya H. Soliman – Tumor Immunology – Best Researcher Award

Ms.Aya H. Soliman - Tumor Immunology - Best Researcher Award

German University in Cairo - Egypt

AUTHOR PROFILE

Scopus

Orcid 

EARLY ACADEMIC PURSUITS:

Aya H. Soliman's academic journey commenced with a fervent pursuit of knowledge. Her early years were marked by a dedication to learning, demonstrating an insatiable curiosity and a penchant for academic excellence. Whether it be notable achievements, academic milestones, or early influences, this period laid the foundation for her future endeavors.

PROFESSIONAL ENDEAVORS:

Embarking on a path of professional growth, Soliman transitioned seamlessly from academia to the professional realm. Her career trajectory reflects a commitment to applying theoretical knowledge to real-world challenges. A closer examination of her professional undertakings unveils a strategic and purposeful approach to making significant contributions in her chosen field.

CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR IMMUNOLOGY

Soliman's contributions to her field are nothing short of groundbreaking. Her research focus is characterized by a meticulous exploration of pertinent issues, coupled with innovative methodologies. By delving into specific themes, she has enriched the academic landscape with fresh perspectives and novel insights, leaving an indelible mark on her area of expertise.

IMPACT AND INFLUENCE:

The impact of Soliman's work extends far beyond the confines of academia. Her research and professional activities have influenced not only fellow scholars but also practitioners in the field. By contributing to the advancement of knowledge, she has played a pivotal role in shaping industry practices and policies, showcasing a far-reaching influence.

ACADEMIC CITES:

A quantitative measure of Soliman's academic influence lies in the citation of her work. The number of times her research has been referenced underscores its significance within scholarly discourse. Her contributions have become integral to the academic canon, with citations serving as a testament to the enduring relevance of her ideas.

FUTURE CONTRIBUTIONS:

Looking ahead, Soliman's future contributions hold promise for continued innovation and advancement. Anticipating the evolving landscape of her field, she remains poised to address emerging challenges and contribute novel solutions. The trajectory of her future contributions is eagerly awaited, promising to shape the direction of academic and professional discourse.

Notable Publications

Phytochemical-derived tumor-associated macrophage remodeling strategy using Phoenix dactylifera L. boosted photodynamic therapy in melanoma via H19/iNOS/PD-L1 axis. 2023